Nintedanib-Induced Delayed Mucosal Healing after Adjuvant Radiation in a Case of Oropharyngeal Carcinoma.
Nintedanib-Induced Delayed Mucosal Healing after Adjuvant Radiation in a Case of Oropharyngeal Carcinoma.
复制标题
DOI：
10.1159/000526077
复制
发表时间：
2022-05
影响因子：
0.8
通讯作者：
Shirai, Katsuyuki
中科院分区：
文献类型：
--
作者：
Takahashi, Satoru;Endo, Masashi;Fukuda, Yukiko;Ogawa, Kazunari;Nakamura, Michiko;Okada, Kohei;Kawahara, Masahiro;Akahane, Keiko;Nagatomo, Takafumi;Onaga, Ryutaro;Nishino, Hiroshi;Mori, Harushi;Shirai, Katsuyuki
自2001年伊马替尼上市以来，酪氨酸激酶抑制剂被广泛用于恶性肿瘤的化疗。抑制多种分子机制的药物称为多激酶抑制剂（MKI）。NKI是一种MKI，可抑制三种系统中的下游级联反应：血管内皮生长因子受体、成纤维细胞生长因子受体和血小板衍生生长因子受体抑制。它最初是作为非小细胞肺癌的抗癌药物开发的;然而，它也被发现抑制与肺部慢性炎症相关的成纤维细胞的增殖。因此，它被更广泛地用于治疗特发性肺纤维化，一种良性疾病，而不是作为一种治疗剂。几项研究报告了与手术或放疗同时使用MKI相关的不良事件。具体而言，有一份报告警告接受手术的患者不要使用尼达尼布导致伤口愈合延迟。然而，没有具体提到在辐照期间同时使用。我们描述了一例72岁男性患者，在接受尼达尼布治疗良性疾病时，放射性粘膜炎严重延迟恢复。
Since the launch of imatinib in 2001, tyrosine kinase inhibitors are being used in chemotherapy for a wide range of malignant tumors. Drugs that inactivate multiple molecular mechanisms are called multikinase inhibitors (MKIs). Nintedanib is a type of MKI that inhibits downstream cascades in three systems: vascular endothelial growth factor receptor, fibroblast growth factor receptor, and platelet-derived growth factor receptor inhibitions. It was initially developed as an anticancer drug for non-small-cell lung carcinoma; however, it was also found to inhibit the proliferation of fibroblasts associated with chronic inflammation in the lungs. Therefore, it is being more widely used to treat idiopathic pulmonary fibrosis, a benign disease, than as an antineoplastic agent. Several studies have reported adverse events associated with the concurrent use of MKIs with surgery or radiotherapy. Specifically, there has been a report cautioning against delayed wound healing associated with the use of nintedanib in patients undergoing surgery. However, there is no specific mention of its concurrent use during irradiation. We describe a case of a 72-year-old man with severely delayed recovery from radiation mucositis when nintedanib was being administered for benign disease.
登录
查看更多内容
影响因子：
2.9
作者：
Kawasaki K;Hamamoto Y;Fukada J;Adachi M;Sasaki H;Takaishi H;Yoshida K;Kanai T
通讯作者：
Kanai T
DOI：
10.1080/17474124.2021.1973431
发表时间：
2021-09-02
影响因子：
3.9
作者：
Rizzo, Alessandro;Ricci, Angela Dalia;Brandi, Giovanni
通讯作者：
Brandi, Giovanni
影响因子：
6.1
作者：
Rizzo, Alessandro;Dadduzio, Vincenzo;Brandi, Giovanni
通讯作者：
Brandi, Giovanni
DOI：
10.1016/j.ijrobp.2007.01.053
发表时间：
2007-07-15
影响因子：
7
作者：
Elting, Linda S.;Cooksley, Catherine D.;Garden, Adam S.
通讯作者：
Garden, Adam S.
影响因子：
51.1
作者：
Hapani, Sanjaykumar;Chu, David;Wu, Shenhong
通讯作者：
Wu, Shenhong